黑料老司机

You are leaving the 黑料老司机s website. By clicking this link, you will be taken to a website that is independent from 黑料老司机s. The site you are linking to is not controlled or endorsed by 黑料老司机s and 黑料老司机s is not responsible for the content provided on that site.

ACCEPT
CANCEL

    This page is intended for Healthcare Professionals only. Are you a Healthcare Professional?

    Yes No

    PIPELINE

    黑料老司机s is developing next generation targeted radiotherapeutics to transform the clinical management of patients with cancer.

    The company has acquired exclusive worldwide rights to radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) targeted technology for therapeutic use and has a research programme initially focused on prostate cancer. The rhPSMA molecule is being investigated in two programmes; one using the beta emitting radioisotope lutetium 177 (177Lu), and one using the alpha emitter actinium 225 (225Ac).

    OUR PIPELINE

    黑料老司机s is investigating the use of the rhPSMA molecule for therapy with the addition of an alpha or beta emitting radioisotope.

    Product / Candidate
    Disease / Therapeutic Area
    Application
    Disease / Therapeutic Area
    Application
    Phases
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    177Lu-rhPSMA-10.1
    Prostate Cancer
    Radiopharmaceutical Therapy
    Prostate Cancer
    Radiopharmaceutical Therapy
    Preclinical
    Phase 1
    Phase 2
    Phase 3
    225Ac-rhPSMA-10.1
    Prostate Cancer
    Radiopharmaceutical Therapy
    Prostate Cancer
    Radiopharmaceutical Therapy
    Preclinical
    Phase 1
    Phase 2
    Phase 3

    177Lu-rhPSMA-10.1 is currently being studied to evaluate its safety profile, tolerability, radiation dosimetry and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (NCT05413850).

    PP-UK-0650 / October 2023